Cyclooxygenase inhibitory and antioxidant bioassay-directed extraction and purification of celery seeds yielded sedanolide (1), senkyunolide-N (2), senkyunolide-J (3), 3-hydroxymethyl-6-methoxy-2,3-dihydro-1H-indol-2-ol (4), L-tryptophan (6), and 7-[3-(3,4-dihydroxy-4-hydroxymethyl-tetrahydro-furan-2-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy]-5-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chromen-4-one (7). The structures of compounds 1-7 were determined using spectroscopic methods. Compound 4 is reported here for the first time. At 250 µg ml -1 , compounds 1-4, 6 and 7 displayed prostaglandin H endoperoxide synthase-I (COX-I) and prostaglandin H endoperoxide synthase-II (COX-II) inhibitory activities at pH 7. The acetylated product (5) of compound 4 also inhibited COX-I and COX-II enzymes when tested at 250 µg ml -1 . Compounds 6 and 7 exhibited good antioxidant activity at concentrations of 125 and 250 µg ml -1 . Only compounds 1-3 exhibited topoisomerase-I and -II enzyme inhibitory activity at concentrations of 100, 200 and 200 µg ml -1 , respectively.
Introduction
A review of the literature indicates that celery has been cultivated for the last 3000 years, notably in pharaonic Egypt, and was known in China in the fifth century BC (Chevalier, 1998) . Celery has been used as a food, and at various times both the whole plant and the seeds have been consumed as a medicine.
The characteristic odor of celery essential oil is due to a series of phthalide derivatives (Bjeldanes and Kim, 1977) . Sedanolide, sedanonic anhydride, 3-n-butyl phthalide, and other minor phthalides are reported to be the major constituents of celery seed oil (Lund, 1978) . Celery seed or celery seed extracts are used as flavoring agents for preparing herbal combinations sold as dietary supplements, and also in antirheumatic formulations. Celery seeds are also implicated in arthritic pain relief, for treating rheumatic conditions and gout (Chevalier, 1998; Bjeldanes and Kim, 1977; Satyavati and Raina, 1976) . Other reports on the medicinal properties of celery seeds were related to asthma and bronchitis and, when used in combination with other herbs, to reduction of blood pressure (Chevalier, 1998; Satyavati and Raina, 1976) . Nitrogenous compounds in celery seed essential oil have been reported to have effects on the central nervous system (Satyavati and Raina, 1976; Kulshrestha et al., 1967) . A. graveolens extracts were assessed for their antiinflammatory activity in intact rats by measuring the suppression of carageenan-induced paw edema (Al-Hindawi et al., 1989) . However, any link between known constituents in the celery plant with the observed antiinflammatory activity was not established.
The research published so far on A. graveolens seeds has focused primarily on the bioactivity of crude extracts. In this paper, we report a novel compound and novel biological activities of compounds from celery seed.
Materials and Methods

Plant Material
Celery seeds were donated by Asgrow Seed Company, Kalamazoo, Michigan and stored at -20 °C until extraction. The silica gel used for VLC and MPLC was Merk Silica gel 60 (30-70 µm particle size). For preparative HPLC (LC-20, Japan Analytical Industry Co., Tokyo) purification, two JAIGEL-ODS, A-343-10 (20 mm × 250 mm, 10 µm, Dychrom, Santa Clara, CA) columns were used in tandem. Peaks were detected using a UV detector equipped with a model D-2500 Chromato-integrator (Hitachi, Tokyo). All solvents were ACS reagent grade and were purchased from Aldrich Chemical Co., Inc.
Extraction and Isolation
The ground seeds (905 g) were extracted with hexane followed by MeOH to yield 20 g of MeOH extract. The MeOH extract (19 g) was stirred with hexane (2 × 400 ml, 15 min) to yield hexane-soluble (7.4 g) and -insoluble (11.5 g) fractions. The hexane-soluble fraction (6 g) was fractionated further by VLC, followed by MPLC on silica gel using hexane with increasing amounts of acetone, and finally with MeOH as eluent. The fractions collected were: A (404 mg, hexane-acetone, 4:1, 250 ml); B (142 mg, hexane-acetone, 2:1, 80 ml); C (483 mg, hexane-acetone, 2:1, 100 ml); D (79 mg, hexane-acetone, 2:1, 120 ml); E (61 mg, hexane-acetone, 1:1, 100 ml); F (89 mg, hexane-acetone, 1:1, 200 ml); G (35 mg, hexane-acetone, 1:1, 100 ml); H (14 mg, 100% acetone, 20 ml); I (33 mg, 100% acetone, 130 ml), and J (8 mg, 100% MeOH, 250 ml). Topoisomerase and cyclooxygenase bioassays of fractions A-J revealed that fraction B was active. The bioactive fraction B (135 mg) was purified by preparative TLC (hexane-acetone, 20:1 × 3) to yield three major bands: I (48 mg, R f 0.18); II (65 mg, R f 0.35) and III (16 mg, R f 0.50). Band II was biologically active and was further purified by repeated preparative TLC (hexane-ether 8:1 × 4 and 2:1 × 1) to yield a pure compound, 1 (22 mg).
The hexane-insoluble fraction (11 g) of the MeOH extract was separated into CHCl 3 -soluble (2.1 g) and -insoluble (8.2 g) fractions by stirring with CHCl 3 (2 × 50 ml, 15 min). The CHCl 3 soluble fraction (2.1 g) was further separated into hexane-soluble (607 mg) and -insoluble (1.5 g) fractions. The hexane-insoluble fraction was further separated into methanol-water (75:25 v/v)-soluble and -insoluble fractions by removing the precipitate through centrifugation. The aqueous MeOH portion (684 mg) was purified by preparative HPLC using methanol-water (75:25 v/v) as the mobile phase at a flow rate of 3 ml/min -1 . Among the 8 fractions collected, the active fraction B (R t = 48 min, 75 mg) was purified further by HPLC using methanol-water (60:40 v/v) as the mobile phase at a flow rate of 2 ml/min -1 . This yielded a mixture of compounds 2 and 3 (R t = 65 min, 12 mg) and a pure compound 4 (R t = min, 8.5 mg). The mixture of compounds 2 and 3 was separated into pure compounds 2 and 3 by HPLC using H 2 O-THF (90:10 v/v) as the mobile phase at a flow rate of 4 ml /min -1 . The acetylation of 4 was performed according to the published procedure (Ramsewak et al., 1999) to yield compound 5.
The CHCl 3 -insoluble fraction (10.2 g) of the MeOH extract, enriched with more extraction of A. graveolens seeds, was partitioned into MeOH-water (75:25 v/v)-soluble (8 g) and -insoluble fractions (1.6 g) by removing the precipitate through centrifugation. The aqueous MeOH portion (7.5 g) was fractionated further by MPLC on a C 18 silica column. The fractions collected were: A (5.25 g, MeOH:H 2 O, 50:50, 100 ml); B (1.59 g, MeOH:H 2 O, 50:50, 130 ml); C (126.6 mg, MeOH:H 2 O, 70:30, 160 ml); D (47.1 mg, MeOH:H 2 O, 90:10, 60 ml); E (139.2 mg, MeOH:H 2 O, 90:10, 120 ml); F (75.9 mg, MeOH:H 2 O, 90:10, 100 ml) and G (161.7 mg, 100% MeOH, 225 ml). The bioactive fraction E was purified by preparative HPLC (LC-20, Japan Analytical Industry Co., Tokyo) using methanol-water (60:40 v/v) as the mobile phase at the flow rate of 3 ml/min -1 . This yielded the bioactive compound 7 (R t = 54 min, 4.5 g). The MPLC fraction B (1.5 g) was separated into MeOH-soluble (1.2 g) and -insoluble (200 mg) fractions through centrifugation. The MeOH-soluble fraction (1.2 g) was fractionated further into four fractions by MPLC on a C 18 silica column with MeOH-H 2 O (60:40, 540 ml) at a 2 ml/min -1 flow rate. Bioactive fraction four (125 mg) was purified by preparative HPLC using MeOH-H 2 O (30:70 v/v) as the mobile phase at a flow rate of 3 ml/min -1 to yield the pure compound 6 (R t = 84.8 min, 5.5 mg).
• Compound 4: thin, glass-like film; IR (NaCl, cm -1 ) Vmax 3372 (broad, intense peak), 2936, 1745, 1607, 1518, 1464, 1273, 1034; 1 H NMR (CDCl 3 , 300 MHz) δ 3.08 (m, 1H, H-3), 3.86 (dd, 1H, J = 6, 2.1 Hz, H-8a), • Acetylation product of compound 4 (5):
1 H NMR (CDCl 3 , 300 MHz) δ 2.04 (s, 3H, -OAc), 2.28 (s, 3H, -OAc), 3.08 (m, 1H, H-3), 3.84 (s, 3H, H-9), 3.92 (dd, 1H, J = 9, 3 Hz, H-8a), 4.26 (dd, 1H, J = 9, 3 Hz, H-8b), 4.78 (d, 1H, J = 4 Hz, H-2), 6.81 (m, 1H, H-7), 6.86 (m, 1H, H-5), 6.88 (m, 1H, H-4).
• 
Cyclooxygenase Inhibitory Assay
Pure compounds 1-7 were assessed for their cyclooxygenase inhibitory activity at 37 °C by monitoring the initial rate of O 2 uptake using an O 2 electrode (Instech Laboratories, Inc., 5209 Militia Road, Plymouth Meeting PA 19462-1216) (Laneuville et al., 1994) . Cyclooxygenase-I (COX-I) activities were measured using prostaglandin H synthase isozymes-I (PGHS-I) from ram seminal vesicles. Cyclooxygenase-II (COX-II) activities were measured using human PGHS-II enzyme obtained from cloned insect cell lysate. Each assay mixture contained 600 µl of 0.1 M Tris buffer (pH 7), 1 mM phenol, 100 µM arachidonic acid and 17 µg hemoglobin. Cyclooxygenase activities were initiated by the addition of 10 µl of COX-I or 20 µl of COX-II enzymes. Instantaneous inhibition was determined by measuring the cyclooxygenase activity initiated by adding aliquots of microsomal suspensions of PGHS-I (10 µM O 2 min -1 cyclooxygenase activity/aliquot) to assay mixtures containing 10 µM arachidonate and 1-250 µg ml -1 concentrations of the test compounds. Ibuprofen and naproxen were assayed at their IC 50 values, 2.52 µg ml -1 and 2.06 µg ml -1 concentrations, respectively.
Antioxidant Assay
Antioxidant bioassays were performed on crude extracts and pure compounds by analysis of liposome oxidation using fluorescence spectroscopy (Arora et al., 1994) . A mixture containing 5 µM of 1-steroyl-2-linoleoyl-sn-glycerol-3-phosphocholine (Avanti Polar lipids, Inc., Alabaster, AL) and 5 µM of the fluorescence probe 3-[p-(6-phenyl)-1,3,5-hexatrienyl]phenylpropionic acid (molecular Probes, Inc., Eugene, OR) was dried in a foil-covered, round-bottom flask under vacuum using a rotary evaporator at room temperature. MBSE buffer (500 µl), consisting of 0.15 M NaCl, 0.1 mM EDTA (Ethylenediaminetetraacetic acid disodium salt) and 10 mM MOPS [3-(N-morpholine propane sulfonic acid), adjusted to pH 7] was used to suspend this lipid film. Buffer solutions were treated with Chelex 100 chelating resin to remove trace metal ions. The lipid-buffer suspension was subjected to 10 freezethaw cycles using a dry ice-EtOH bath. After the last thaw, the lipid-buffer suspension was extruded 29 times through a Liposo Fast extruder (Avestin, Inc., Ottawa, Canada) containing a polycarbonate membrane with a pore size of 100 nm to produce large unilamellar liposomes (LUVs). A 20-µl aliquot of this liposome suspension was diluted to a final volume of 2 ml in Chelex 100 treated HEPES buffer (100 µl, pH 7), 1 M NaCl (200 µl), N 2 -sparged water and DMSO solution containing the test compound (20 µl), vortexed, and placed in the cuvette holder of the spectrophotometer. Peroxidation was then initiated by the addition of 20 µl of 0.5 mM FeCl 2 stock solution to achieve a final concentration of 5µM of Fe +2 in the presence of test compounds or crude extract dissolved in DMSO. The control sample contained neither Fe +2 or the test compounds. The positive controls BHA, BHT, TBHQ, and α-tocopherol (Vitamin E) were tested at final concentrations of 1.8, 2.2, 1.66 and 4.31 µg ml -1 , respectively whereas compounds 1-7 were tested at final concentrations of 25-250 µg ml -1 . Fluorescence intensities of these liposome solutions were measured at an excitation wavelength of 384 nm for every 3 min over a period of 21 min using a Turner model 450 digital fluorometer (Barnstead Thermolyne, Dubuque, IA). The decrease of relative fluorescence intensity over time indicated the rate of peroxidation. Relative fluorescence was calculated by dividing the fluorescence value at a given time point (F t ) by that at t = 0 min (F 0 ).
Topoisomerase-I and -II Inhibitory Assay
Compounds 1-3 were evaluated for topoisomerase-I and -II inhibitory activities according to the reported procedure (Nair et al., 1989) . The S. cerevisiae mutant cell cultures, JN394, JN394t -1 and JN394t -2-5 , used for the topoisomerase inhibitory assays were cultured in petri dishes containing YPDA medium (20 ml). Two to three ml of successful. Based on spectral data of the natural product and its acetate, compound 4 was deduced to be 3-hydroxymethyl-6-methoxy-2,3-dihydro-1H-indol-2-ol. Compound 4 is a novel natural product.
The CHCl 3 -insoluble fraction of MeOH extract of A. graveolens seeds was partitioned into MeOH-watersoluble and -insoluble fractions. The aqueous MeOH portion was fractionated by MPLC using a C 18 silica column and the active fractions were purified by repeated preparative HPLC, to yield pure compounds 6 and 7.
The structure of compound 6 was deduced by detailed analysis of the 1 H-and 13 C-NMR spectra and confirmed by HMQC and HMBC spectral data.
1 Hand 13 C-NMR chemical shift values of compound 6 were in agreement with the reported values for L-tryptophan (Lee and Phillips, 1992) . Detailed analyses of the 1 H-and 13 C-NMR spectra helped to characterize the structure of 7. In the 1 H-NMR spectrum of 7, a doublet at δ 7.84 and a doublet of doublet at δ 6.80 suggested that the B ring in 7 was substituted at C-3′ and C-4′. The signal at δ 7.48, a singlet integrated for one proton, was assigned to H-3. Another three aromatic protons (δ 6.84, 6.62 and 6.53), all doublets with coupling constants of 3, 3 and 2.4 Hz, respectively, indicated a meta coupling and were thus assigned to H-8, H-6 and H-2′, respectively. Two doublets at 5.45 and 5.15 ppm were assigned to the anomeric protons of fructose and glucose, respectively. The sugar identities were further confirmed by 13 C-NMR experiments. Most of the 13 C-NMR spectral data for compound 7 were in agreement with the published data for apiin (Forgacs et al., 1978) . The difference between apiin and compound 7 is the presence of a methoxy group at C-3′. This methoxy group appeared as a singlet at δ 3.34 in the 1 H-NMR spectrum and corresponded to a peak at δ 55.9 in its 13 C-NMR spectrum. Compound 7 was identified as 3'-methoxy apiin. Although compound 7 was previously reported from celery seeds (Sheshadri and Vydeeswaran, 1971) , this is the first report of 1 H-and 13 C-NMR spectral data for 7. For antioxidant and cyclooxygenase inhibitory assays, test compounds were prepared in DMSO and were tested at varying concentrations ranging from 50-250 µg ml -1 . All test compounds demonstrated good COX-I and COX-II inhibitory activities at 250 µg ml -1 (Fig. 2) . Compounds 1-3 exhibited about 24, 28 and 31% COX-I inhibition and 25, 30 and 31% COX-II inhibition at 250 µg ml -1 , respectively. Compounds 4 and its acetate, 5, demonstrated 52.3 and 31.8% of COX-I inhibition and 39.8 and 28.3 % of COX-II inhibition, respectively, when assayed at 250 µg ml -1 (Fig. 2) . In a dose-response study, compound 4 showed 30% of COX-II inhibition at 25 µg ml -1 . At concentrations lower than 250 µg ml -1 compounds 1-3, 6 and 7 did not show significant COX-I or -II enzyme inhibiphysiological saline solution were added to fully grown plates of each organism and then suspensions were diluted to obtain 5 × 10 6 CFU ml -1
. Bioassays were conducted by spreading 50 µl of the desired cell suspension on to petri dishes of the YPDA media. DMSO or test compound dissolved in DMSO (20 µl) were spotted carefully on the bioassay plates at varying concentrations. The plates were allowed to dry in a laminar flow hood and then incubated at 27 °C for 72 h. The zone of inhibition was measured in mm. Minimum inhibitory concentrations (MIC 100 ) for compounds 1-3 were determined according to the published procedure (Nair et al., 1989) .
Results
Compounds 1-3 were characterized as sedanolide (1), senkyunolide-N (2) and senkyunolide-J (3), and their 1 H-and 13 C-NMR spectral data were identical to those of published values (Zheng et al., 1993; Naito et al., 1992) .
The structure of compound 4 was deduced using 1 Hand 13 C-NMR, DEPT, HMQC, HMBC, IR and GCMS spectral techniques. The 1 H-NMR spectrum of compound 4 gave a singlet, integrated for three protons at 3.88 ppm, which corresponded to a methoxy group. A broad peak at 5.6 ppm was determined to be an -NH group, as indicated by the disappearance of this peak with D 2 O shake in its 1 H-NMR spectrum. The 13 C-NMR spectrum of 4 revealed ten peaks, which were assigned to three aromatic carbons (δ 108.5, 114.2, 118.9), one methoxy carbon (δ 55.92), three quaternary carbons (δ 132.8, 145.2, 146.6), two CH (δ 85.8, 54 .09) and one CH 2 (δ 71.6), as indicated by the DEPT spectrum of 4. Both HMQC and HMBC spectral data provided confirmation of the structure proposed for compound 4. The important connectivities in the HMBC spectrum of 4 were those observed for C-3a and C-8. The signal for C-3a correlated to H-3 and H-2 signals, while C-8 displayed cross signals to H-2. Also, the correlation of C-2 to H-8a and H8b, as well as the correlation of C-3 to H-8a, H-8b and H-2, supported the proposed structure. Three methoxy protons showed correlations to C-6. The presence of OH groups in 4 was suggested by a broad peak at 3372 cm ) and naproxen (2.52 µg ml -1 ) showed 54.3 and 47.5% COX-I inhibition, and 39.8 and 41.3% COX-II inhibition, respectively (Fig. 2) . Compounds 6 and 7 also showed 31 and 29% COX-I inhibition and 32 and 21% COX-II inhibition (Fig. 2) at 250 µg ml -1 , respectively. Compounds 1-3 were tested for their topoisomerase-I and -II inhibitory activities on S. cerevisiae mutant strains at different concentrations. Compounds 1-3 demonstrated topoisomerase-I and -II inhibitory activities in this bioassay. The MIC 100 value determination of compounds 1-3 indicated that compound 1 completely inhibited topoisomerase-I and -II activities at 100 µg ml -1 , while 2 and 3 inhibited only topoisomerase-II at 200 µg ml -1 . Compound 6, L-tryptophan, exhibited 90% antioxidant activity at 250 µg ml -1 (Fig. 3) after 21 min. It also . Ibuprofen and naproxen were tested at 2.06 and 2.52 µg ml -1 , respectively. Vertical bars represent the standard deviation of each data point (n = 2).
Cox-I; ᮀ Cox-II.
showed antioxidant activity similar to Vit.-E at 25 µg ml -1
. Compound 7 also inhibited lipid peroxidation induced by Fe 2+ at 250 and 125 µg ml -1 concentrations. At concentrations lower than 125 µg ml -1 , the antioxidant activities of compounds 6 and 7 diminished significantly. Compounds 1-5 did not show significant antioxidant activities (data not shown).
Discussion
All test compounds, 1-7, showed COX-I and COX-II inhibitory activities at 250 µg ml -1 . Compound 4 exhibited the best COX-I and COX-II inhibitory activities among all test compounds, at 250 µg ml -1 concentration. Compound 4 showed better or comparable cyclooxygenase enzyme inhibition than positive controls. The acetylated product (5) of compound 4 also demonstrated good COX-I and COX-II inhibitory activities. There was no significant difference between COX-I and COX-II inhibition at different test concentrations of compound 1. Compounds 2 and 3 showed similar inhibitory activities for COX-I and COX-II enzymes at their respective concentrations. COX-I inhibition decreased with a decrease in concentration for both compounds 2 and 3.
Compounds 1-3 demonstrated topoisomerase-I and -II inhibitory activities in this bioassay. Among S. cerevisiae mutant strains, JN394 is hypersensitive to topoisomerase-I poisons, while strain JN394 t-1 lacks the top-I gene and therefore shows a lack of response to topoisomerase-I poisons. The strain JN394 t-2-5 carries the top-II gene, which is resistant to topoisomerase-II poisons but responds to topoisomerase-I poisons. The MIC 100 value determination of compounds 1-3 indicated that compound 1 completely inhibited topoisomerase-I and -II activities at 100 µg ml -1 , while 2 and 3 inhibited only topoisomerase-II enzyme at 200 µg ml -1 . Indole-like compounds and indole alkaloids found in the plant kingdom have pharmacological properties and are reported as antitumor agents (Hutchinson, 1980; Wall et al., 1966) . Tryptophan, a precursor for indole biosynthesis, is well documented for its effect on central nervous system and for its therapeutic use in depression, mania and aggression (Young et al., 1984) . It is reported that tryptophan as a dietary supplement, when combined with a high carbohydrate and reduced protein and fat diet, resulted in a significant reduction in the pain intensity experienced by chronic pain patients. The observed biological activities of compounds 4-6 in our laboratory are in agreement with the anecdotal use of celery seeds to alleviate gout and arthritic pain. ). Antioxidant activities of commercial antioxidants, TBHQ, BHT, BHA and Vit.-E were evaluated at 1.8, 2.2, 1.66 and 4.31 µg ml -1 , respectively. Data represent the mean of duplicate experiments. Statistical analysis was performed using ANOVA (p ≤ 0.01), and the means were compared by calculating least significant difference (LSD).
